Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2627]

ASCO 2013: Novel drug that inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer

ASCO 2013: Novel drug that inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer

Researchers provide rationale for use of targeted immunotherapy in sarcomatoid lung carcinomas

Researchers provide rationale for use of targeted immunotherapy in sarcomatoid lung carcinomas

FDA approves erlotinib with EGFR mutation test for advanced NSCLC

FDA approves erlotinib with EGFR mutation test for advanced NSCLC

EMCTO 2013: Initial results from the largest prospective study of pulmonary metastasectomy in patients with colorectal cancer

EMCTO 2013: Initial results from the largest prospective study of pulmonary metastasectomy in patients with...

EMCTO 2013: Stereotactic ablative radiotherapy is an effective alternative in patients with multiple primary lung cancers

EMCTO 2013: Stereotactic ablative radiotherapy is an effective alternative in patients with multiple primary lung...

EMCTO 2013: Evaluation of performance of lung cancer screening strategy in the first three rounds of the NELSON trial

EMCTO 2013: Evaluation of performance of lung cancer screening strategy in the first three rounds of the NELSON...

EMCTO 2013: Different survival outcome following diagnosis of metastatic bone disease shown for EGFR mutated NSCLC patients in small retrospective study

EMCTO 2013: Different survival outcome following diagnosis of metastatic bone disease shown for EGFR mutated NSCLC...

EMCTO 2013: Meta-analysis slightly favours platinum-based first-line treatment in patients with advanced/metastatic NSCLC

EMCTO 2013: Meta-analysis slightly favours platinum-based first-line treatment in patients with advanced...

EMCTO 2013: A study of simultaneous occurrence of EGFR mutations and HER2 gene amplifications in large series of NSCLC

EMCTO 2013: A study of simultaneous occurrence of EGFR mutations and HER2 gene amplifications in large series of...

EMCTO 2013: First-line gefitinib effective and well tolerated in Caucasian patients with EGFR mutation-positive NSCLC

EMCTO 2013: First-line gefitinib effective and well tolerated in Caucasian patients with EGFR mutation-positive...

More from ecancer